Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Thomas J. George

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6249-9180; OpenAlex author ID A5020154592. Sources: ClinicalTrials.gov.

Their work

Papers
40 (first author 3, last author 4)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
103
Papers, trials and grants by year

2011: 1 trial · 2012: 1 trial · 2013: none · 2014: 3 papers · 2015: 3 papers · 2016: 2 papers · 2017: 6 papers · 2018: 1 paper, 1 trial · 2019: 4 papers · 2020: 1 paper · 2021: 2 papers · 2022: 6 papers · 2023: 5 papers · 2024: 1 paper · 2025: 1 paper · 2026: 5 papers

Papers 40

  1. Renin-angiotensin-aldosterone system inhibitors and risk of pancreatic cancer in older adults: A target trial emulation. First author DOI 10.1002/ijc.70438↗
  2. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  3. Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial. Co-author DOI 10.1093/oncolo/oyag250↗
  4. Neoadjuvant Therapy for Localized Pancreatic Cancer. Co-author DOI 10.3390/cancers18061011↗
  5. Pancreatoblastoma: A Descriptive and Comparative Analysis with Pancreatic Ductal Adenocarcinoma Using SEER Data. Co-author DOI 10.3390/cancers18162642↗
  6. A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. Co-author DOI 10.1016/j.neo.2024.101070↗
  7. Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jcsm.13390↗
  8. National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.06.018↗
  9. Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans. Co-author DOI 10.1016/j.jnma.2023.01.008↗
  10. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2208470↗
  11. Ethical Considerations of Biopsies in Early-Stage Pancreatic Cancer. Co-author DOI 10.1200/op.23.00044↗
  12. A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. Last author DOI 10.2217/fon-2023-0256↗
  13. Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery. Co-author DOI 10.1002/cam4.4416↗
  14. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable … Co-author DOI 10.1097/sla.0000000000004669↗
  15. Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials. Co-author DOI 10.1200/jco.21.02492↗
  16. Association of social determinants of health with late diagnosis and survival of patients with pancreatic cancer. Co-author DOI 10.21037/jgo-21-788↗
  17. Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/bios12040206↗
  18. Associations of Overall Survival with Geriatric Nutritional Risk Index in Patients with Advanced Pancreatic Cancer. First author DOI 10.3390/nu14183800↗
  19. Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1002/onco.13853↗
  20. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pan… Co-author DOI 10.3390/cancers13040809↗
  21. Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes. Co-author DOI 10.1002/cam4.3042↗
  22. Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor … Co-author DOI 10.1002/cam4.2180↗
  23. The Proteome of Pancreatic Cancer-Derived Exosomes Reveals Signatures Rich in Key Signaling Pathways. Co-author DOI 10.1002/pmic.201800394↗
  24. Using photography to explore psychological distress in patients with pancreatic cancer and their caregivers: a qualitative study. First author DOI 10.1007/s00520-018-4330-y↗
  25. Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/thno.28745↗
  26. Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. Last author DOI 10.1007/s12029-017-0021-z↗
  27. A Novel Microfluidic Device for Isolation of Circulating Tumor Cells from Pancreatic Cancer Blood Samples. Co-author DOI 10.1007/978-1-4939-7144-2_3↗
  28. The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. Last author DOI 10.1007/s11864-017-0515-8↗
  29. A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2016.09.038↗
  30. Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Huma… Co-author DOI 10.1097/mpa.0000000000000843↗
  31. Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. Co-author DOI 10.1158/0008-5472.can-16-1765↗
  32. Human pancreatic cancer xenografts recapitulate key aspects of cancer cachexia. Co-author DOI 10.18632/oncotarget.13593↗
  33. Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. Co-author DOI 10.1016/j.ajpath.2016.02.009↗
  34. Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-15-1256↗
  35. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Last author DOI 10.1002/cam4.444↗
  36. Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in hum… Co-author DOI 10.1007/s00262-015-1760-y↗
  37. The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. Co-author DOI 10.1186/s12885-015-1820-x↗
  38. "Tissue is the issue": circulating tumor cells in pancreatic cancer. Co-author DOI 10.1007/s12029-014-9638-3↗
  39. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Co-author DOI 10.1039/c3lc51017d↗
  40. Src inhibition is still a relevant target in pancreatic cancer. Co-author DOI 10.1634/theoncologist.2013-0410↗

Trials 3

  1. A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcin… Principal investigator NCT03483038↗
  2. Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma Principal investigator NCT01652976↗
  3. Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma Principal investigator NCT01470417↗

Closest collaborators

The 25 strongest of 103 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steven J. Hughes · 20 shared papers, 2015–2026 · strength 2.56
  2. Jose Gilberto Trevino · 17 shared papers, 2014–2025 · strength 1.62
  3. Ibrahim Nassour · 5 shared papers, 2023–2026 · strength 1.11
  4. Jesus C. Fabregas · 5 shared papers, 2022–2026 · strength 1.01
  5. Patrick W. Underwood · 5 shared papers, 2019–2026 · strength 0.92
  6. Kathryn E. Hitchcock · 4 shared papers, 2023–2026 · strength 0.82
  7. Z. Hugh Fan · 7 shared papers, 2014–2026 · strength 0.82
  8. Sherise Chantell Rogers · 4 shared papers, 2023–2026 · strength 0.74
  9. Andrew R. Judge · 7 shared papers, 2017–2024 · strength 0.74
  10. Alessandro Paniccia · 3 shared papers, 2023–2026 · strength 0.72
  11. Ryan Michael Thomas · 8 shared papers, 2015–2026 · strength 0.70
  12. Song Han · 6 shared papers, 2015–2025 · strength 0.67
  13. Kelly M. Herremans · 4 shared papers, 2020–2024 · strength 0.66
  14. Andrea N. Riner · 4 shared papers, 2020–2024 · strength 0.66
  15. Sarah M. Judge · 5 shared papers, 2017–2024 · strength 0.55
  16. Abdul Qahar Khan Yasinzai · 2 shared papers, 2026 · strength 0.55
  17. Jordan A. McKean · 2 shared papers, 2026 · strength 0.55
  18. Chen Liu · 9 shared papers, 2014–2019 · strength 0.52
  19. Miles E. Cameron · 4 shared papers, 2019–2022 · strength 0.46
  20. Daniel Delitto · 8 shared papers, 2015–2017 · strength 0.44
  21. K.E. Behrns · 8 shared papers, 2015–2017 · strength 0.44
  22. Bo Han · 2 shared papers, 2022–2023 · strength 0.41
  23. Omar Roger Kayaleh · 2 shared papers, 2023–2026 · strength 0.39
  24. Vignesh Vudatha · 2 shared papers, 2022–2024 · strength 0.34
  25. Shannon Margaret Wallet · 6 shared papers, 2015–2017 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.